Rhythm Pharmaceuticals, Inc. reports results for the quarter ended September 30 - Earnings Summary

What happened

Rhythm Pharmaceuticals reported a quarterly adjusted loss of 61 cents per share, better than the 71 cents analysts expected. Revenue rose 79.6% to $92.13 million, above the $85.27 million estimate. The company posted a quarterly loss of $42.35 million.

Confirmed

Global impact / market context

A smaller loss than expected plus much faster revenue growth shows the company is selling more while keeping costs in check. That can ease the need to raise outside cash soon, which matters because the company is still unprofitable.

Analyst inference

Analysts rate the stock a buy, and the $143 median price target sits 34.7% above the $93.44 last close. That target implies analysts see room for gains, yet the shares had lost value over the quarter and year.

Analyst inference

What to watch

1. Watch whether revenue keeps growing near this pace, since the 79.6% yearly rise to $92.13 million was a key reason results topped analyst estimates. Confirmed
2. Track whether the company narrows its $42.35 million quarterly loss, because continued losses would likely push it to raise more money. Proposed
3. Note the gap between the $143 price target and the $93.44 close. A shrinking gap would signal growing confidence, while a widening one suggests doubts. Analyst inference

Evidence

• Original source link unavailable